Collegium Pharmaceutical, Inc. (NASDAQ:COLL) major shareholder Longitude Capital Partners, Ll sold 1,000,000 shares of the firm’s stock in a transaction on Friday, December 8th. The shares were sold at an average price of $17.34, for a total value of $17,340,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Collegium Pharmaceutical, Inc. (COLL) opened at $17.91 on Wednesday. Collegium Pharmaceutical, Inc. has a fifty-two week low of $7.37 and a fifty-two week high of $20.92.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.28. The firm had revenue of $11.95 million for the quarter, compared to analyst estimates of $5.31 million. Collegium Pharmaceutical had a negative return on equity of 77.11% and a negative net margin of 447.83%. Collegium Pharmaceutical’s revenue was up 2814.6% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.13) earnings per share. analysts anticipate that Collegium Pharmaceutical, Inc. will post -2.52 EPS for the current year.

A number of research analysts have recently commented on COLL shares. Piper Jaffray Companies reissued a “buy” rating and set a $14.00 price target on shares of Collegium Pharmaceutical in a report on Friday, September 8th. Zacks Investment Research raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a report on Monday, November 13th. HC Wainwright reissued a “buy” rating and set a $21.00 price target on shares of Collegium Pharmaceutical in a report on Wednesday, November 8th. Needham & Company LLC reissued a “buy” rating and set a $25.00 price target on shares of Collegium Pharmaceutical in a report on Friday, October 6th. Finally, Jefferies Group reissued a “buy” rating and set a $15.00 price target on shares of Collegium Pharmaceutical in a report on Friday, October 6th. Two research analysts have rated the stock with a sell rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $23.50.

Large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in Collegium Pharmaceutical by 7.8% during the first quarter. Vanguard Group Inc. now owns 806,539 shares of the specialty pharmaceutical company’s stock worth $8,113,000 after acquiring an additional 58,398 shares during the period. Teton Advisors Inc. acquired a new position in Collegium Pharmaceutical during the third quarter worth about $283,000. Bank of New York Mellon Corp grew its holdings in Collegium Pharmaceutical by 60.7% during the second quarter. Bank of New York Mellon Corp now owns 104,961 shares of the specialty pharmaceutical company’s stock worth $1,313,000 after acquiring an additional 39,656 shares during the period. Teachers Advisors LLC grew its holdings in Collegium Pharmaceutical by 98.8% during the second quarter. Teachers Advisors LLC now owns 59,590 shares of the specialty pharmaceutical company’s stock worth $745,000 after acquiring an additional 29,617 shares during the period. Finally, Pier Capital LLC grew its holdings in Collegium Pharmaceutical by 8.1% during the second quarter. Pier Capital LLC now owns 395,658 shares of the specialty pharmaceutical company’s stock worth $4,950,000 after acquiring an additional 29,594 shares during the period. 79.98% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This news story was first posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.watchlistnews.com/collegium-pharmaceutical-inc-coll-major-shareholder-longitude-capital-partners-ll-sells-1000000-shares/1761049.html.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with Analyst Ratings Network's FREE daily email newsletter.